中草药

黄连在治疗炎症性肠病中的作用机制和应用研究进展

PDF下载

中草药 | 综述 2026,57(4): 1546-1558

收起

中草药 |综述 2026 , 57 (4) : 1546 -1558

黄连在治疗炎症性肠病中的作用机制和应用研究进展

全屏

崔西¹, 李航航¹, 翟睿¹, 刘翠翠¹, 史树勋²

作者信息

通讯作者:

史树勋

作者简介:

崔西: 崔西（2000—），女，硕士研究生，研究方向为中医药治疗溃疡性结肠炎的基础研究。E-mail:2290043127@qq.com

Research progress on mechanism and application of Coptidis Rhizoma in treatment of inflammatory bowel disease

CUI Xi, LI Hanghang, ZHAI Rui, LIU Cuicui, SHI Shuxun

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.04.030

文章导航

摘要

收起

炎症性肠病（inflammatory bowel disease，IBD）是一种胃肠道慢性复发性非特异性疾病，发病机制尚不明确，目前尚无根治性疗法。黄连Coptidis Rhizoma作为多成分的天然传统中药，凭借其丰富的化学成分和独特的药理活性，在IBD治疗中展现出多靶点、多途径的调控优势。其核心活性成分为异喹啉类生物碱，包括小檗碱（berberine）、黄连碱（coptisine）、巴马汀（palmatine）、小檗红碱（berberrubine）等。此外，黄连还含有黄酮类、木脂素、有机酸、多糖、萜类化合物等多种活性成分，共同发挥清热燥湿、泻火解毒的功效。现代药理学研究证实黄连及其有效成分可通过抗氧化应激、抗炎、免疫调节、保护肠黏膜屏障、调节肠道菌群、调控糖代谢、胆碱能系统调节等机制对IBD产生治疗作用，通过对近年来黄连及其有效成分对IBD治疗的作用机制及应用进行综述，为黄连在IBD临床标准化制剂开发提供参考。

关键词

黄连 / 炎症性肠病 / 黏膜屏障 / 肠道菌群 / 小檗碱 / 黄连碱 / 巴马汀 / 小檗红碱

Abstract

收起

Inflammatory bowel disease (IBD) is a chronic, recurrent, non-specific gastrointestinal disease with an unclear pathogenesis, and there is no curative treatment at present. As a multi-component natural traditional Chinese medicine, Coptidis Rhizoma shows the advantages of multi-target and multi-pathway regulation in the treatment of IBD with its rich chemical composition and unique pharmacological activity. Its core active ingredients are isoquinoline alkaloids, including berberine, coptisine, palmatine, berberrubine, etc., supplemented by flavonoids, lignans, organic acids, polysaccharides, terpenoids and other components, which have the effect of clearing heat and drying dampness,purgingfire and removing toxin. Modern pharmacological studies have confirmed that Coptidis Rhizoma and its active components exert therapeutic effects on IBD through multiple mechanisms, including antioxidative stress, anti-inflammatory, immunomodulatory, intestinal mucosal barrier protection, regulation of intestinal flora, glucose metabolism modulation, and cholinergic system regulation. This review summarizes the recent advances in the mechanisms and applications of Coptidis Rhizoma and its active ingredients in the treatment of IBD, providing a reference for the development of standardized clinical preparations of Coptidis Rhizoma.

Key words

Coptidis Rhizoma / inflammatory bowel disease / mucosal barrier / intestinal microflora / berberine / coptisine / palmatine / berberrubine

引用本文

崔西, 李航航, 翟睿, 刘翠翠, 史树勋. 黄连在治疗炎症性肠病中的作用机制和应用研究进展. 中草药, 2026 , 57 (4) : 1546 -1558 . DOI: 10.7501/j.issn.0253-2670.2026.04.030

CUI Xi, LI Hanghang, ZHAI Rui, LIU Cuicui, SHI Shuxun. Research progress on mechanism and application of Coptidis Rhizoma in treatment of inflammatory bowel disease[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (4) : 1546 -1558 . DOI: 10.7501/j.issn.0253-2670.2026.04.030

基金

收起

国家医疗质量循证管理持续改进研究项目 (YLZLXZ22G029); 甘肃中医药大学联合科研基金项目 (HXLH-XTCX01); 兰州市科技发展指导性计划项目 (2024-9-83); 甘肃省高校教师创新基金项目 (2025B-114)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Bruner L P, White A M, Proksell S. Inflammatory bowel disease [J]. Prim Care Clin Off Pract, 2023, 50(3): 411-427.
Park S H, Park S H. Personalized medicine in inflammatory bowel disease: Perspectives on Asia [J]. J Gastroenterol Hepatol, 2022, 37(8): 1434-1445.
包云丽, 汪哲, 唐海茹, 等. 1990—2019年中国炎症性肠病疾病负担及变化趋势分析[J]. 中国全科医学, 2023, 26(36): 4581-4586.
Olfatifar M, Zali M R, Pourhoseingholi M A, et al. The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study [J]. BMC Gastroenterol, 2021, 21(1): 204.
姚筱朵, 祖国秀, 沈悦, 等. 基于生物信息学和机器学习的溃疡性结肠炎活动期与非活动期特征基因及靶向中药预测研究[J]. 中国医药导刊, 2025, 27(3): 247-256.
吴立军. 天然药物化学[M]. 6版. 北京: 人民卫生出版社, 2011: 382-386.
王慧文. 超声-酶-海藻糖脂协同提取黄连五种生物碱及其抗炎作用的研究[D]. 哈尔滨: 东北农业大学, 2025.
曾燕凤, 沈霖创, 马志良, 等. 基于现代色谱和核磁共振波谱技术的黄连化学成分系统性研究与鉴定[J]. 广东化工, 2025, 52(18): 148-151.
王晓丽, 彭梅梅, 陈琪, 等. 基于UPLC-Q-TOF-MS/MS技术的经典名方黄连汤化学成分鉴定及网络药理学研究[J]. 中国中药杂志, 2023, 48(5): 1249-1263.
Yang W L, Zhang C Y, Ji W Y, et al. Berberine metabolites stimulate GLP-1 secretion by alleviating oxidative stress and mitochondrial dysfunction [J]. Am J Chin Med, 2024, 52(1): 253-274.
Wang J, Wang L, Lou G H, et al. Coptidis Rhizoma: A comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology [J]. Pharm Biol, 2019, 57(1): 193-225.
张烨, 邓琦, 魏敏, 等. 黄连花薹化学成分的UPLC-Q-Orbitrap HRMS鉴定[J]. 中国实验方剂学杂志, 2021, 27(15): 91-99.
Ju Y, Wang C M, Yu J J, et al. Higenamine inhibits acute and chronic inflammatory pain through modulation of TRPV4 channels [J]. Eur J Pharmacol, 2024, 964: 176295.
Jing W H, Dong S J, Luo X L, et al. Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites [J]. Pharmacol Res, 2021, 164: 105358.
Sahoo D K, Heilmann R M, Paital B, et al. Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease [J]. Front Endocrinol, 2023, 14: 1217165.
Li H, Fan C, Lu H M, et al. Protective role of berberine on ulcerative colitis through modulating enteric glial cells-intestinal epithelial cells-immune cells interactions [J]. Acta Pharm Sin B, 2020, 10(3): 447-461.
余成华, 杨秋雄, 朱春艳, 等. 云黄连根化学成分的研究[J]. 中成药, 2021, 43(8): 2100-2105.
欧阳志伟, 李伶, 覃锋, 等. 岩黄连乙酸乙酯部位化学成分及其抗炎活性研究[J]. 广西植物, 2023, 43(1): 111-119.
Wang L, Zhang S Y, Chen L, et al. New enantiomeric isoquinoline alkaloids from Coptis chinensis [J]. Phytochem Lett, 2014, 7: 89-92.
Li C L, Deng L, Pu M, et al. Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome [J]. J Ethnopharmacol, 2024, 335: 118680.
Fujiwara H, Nonaka G, Yagi A, et al. Studies on the components of the leaves of Coptis japonica Makino. I. The structures of coptiside I and II [J]. Chem Pharm Bull, 1976, 24(3): 407-413.
郝艺铭, 霍金海, 王涛, 等. UPLC-Q-TOF/MS技术分析黄连中非生物碱类成分[J]. 中药材, 2020, 43(2): 354-358.
Jang W Y, Kim M Y, Cho J Y. Antioxidant, anti-inflammatory, anti-menopausal, and anti-cancer effects of lignans and their metabolites [J]. Int J Mol Sci, 2022, 23(24): 15482.
陈斯亮, 刘梦鸽, 史晋宁, 等. 阿魏酸治疗阿尔茨海默病的潜在靶点预测及验证[J]. 药学研究, 2024, 43(5): 428-434.
Ghasemi-Dehnoo M, Amini-Khoei H, Lorigooini Z, et al. Ferulic acid ameliorates ulcerative colitis in a rat model via the inhibition of two LPS-TLR4-NF-κB and NF-κB-INOS-NO signaling pathways and thus alleviating the inflammatory, oxidative and apoptotic conditions in the colon tissue [J]. Inflammopharmacology, 2023, 31(5): 2587-2597.
Zheng C H, Zhong Y C, Zhang W M, et al. Chlorogenic acid ameliorates post-infectious irritable bowel syndrome by regulating extracellular vesicles of gut microbes [J]. Adv Sci, 2023, 10(28): 2302798.
刘舒凌, 李秀连, 梁灵南, 等. 黄连制吴茱萸炮制前后抗炎、抗氧化、抑菌作用研究[J]. 中国药业, 2025, 34(9): 34-39.
武鑫华, 荀思佳, 吴文轩, 等. 黄连的化学成分及药理作用研究进展[J]. 中医药学报, 2024, 52(7): 110-116.
商佳璐, 叶怡馨, 刘玉云, 等. 白术-甘草配伍对其化学成分及健脾作用的相关性研究[J]. 时珍国医国药, 2025, 36(8): 1409-1414.
Cheng H, Zhang D D, Wu J, et al. Atractylodes macrocephala Koidz. volatile oil relieves acute ulcerative colitis via regulating gut microbiota and gut microbiota metabolism [J]. Front Immunol, 2023, 14: 1127785.
Chen Q Q, Ren R R, Zhang Q Q, et al. Coptis chinensis Franch polysaccharides provide a dynamically regulation on intestinal microenvironment, based on the intestinal flora and mucosal immunity [J]. J Ethnopharmacol, 2021, 267: 113542.
Wang X M, Liang F N, Dai Z Y, et al. Combination of Coptis chinensis polysaccharides and berberine ameliorates ulcerative colitis by regulating gut microbiota and activating AhR/IL-22 pathway [J]. J Ethnopharmacol, 2024, 318(Pt B): 117050.
Iborra M, Moret I, Rausell F, et al. Role of oxidative stress and antioxidant enzymes in Crohn’s disease [J]. Biochem Soc Trans, 2011, 39(4): 1102-1106.
Colgan S P, Taylor C T. Hypoxia: An alarm signal during intestinal inflammation [J]. Nat Rev Gastroenterol Hepatol, 2010, 7(5): 281-287.
Meng G B, Li P Y, Du X M, et al. Berberine alleviates ulcerative colitis by inhibiting inflammation through targeting IRGM1[J]. Phytomedicine, 2024, 133: 155909.
Xue L W, Jin X S, Ji T T, et al. Luteolin ameliorates DSS-induced colitis in mice via suppressing macrophage activation and chemotaxis [J]. Int Immunopharmacol, 2023, 124(Pt B): 110996.
Wu J S, Luo Y, Jiang Q, et al. Coptisine from Coptis chinensis blocks NLRP3 inflammasome activation by inhibiting Caspase-1[J]. Pharmacol Res, 2019, 147: 104348.
Liu X F, Zhang X H, Ye L, et al. Protective mechanisms of berberine against experimental autoimmune myocarditis in a rat model [J]. Biomed Pharmacother, 2016, 79: 222-230.
Ma J, Chan C C, Huang W C, et al. Berberine inhibits pro-inflammatory cytokine-induced IL-6 and CCL11 production via modulation of STAT6 pathway in human bronchial epithelial cells [J]. Int J Med Sci, 2020, 17(10): 1464-1473.
Song J, Yang J, Jing S S, et al. Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets [J]. J Neuroimmunol, 2022, 362: 577787.
Li H, Feng C L, Fan C, et al. Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis [J]. Cell Death Dis, 2020, 11(4): 271.
Chen H B, Luo C D, Liang J L, et al. Anti-inflammatory activity of coptisine free base in mice through inhibition of NF-κB and MAPK signaling pathways [J]. Eur J Pharmacol, 2017, 811: 222-231.
Feng M, Kong S Z, Wang Z X, et al. The protective effect of coptisine on experimental atherosclerosis ApoE (−/−) mice is mediated by MAPK/NF-κB-dependent pathway [J]. Biomed Pharmacother, 2017, 93: 721-729.
Choi S B, Bae G S, Jo I J, et al. Berberine inhibits inflammatory mediators and attenuates acute pancreatitis through deactivation of JNK signaling pathways [J]. Mol Immunol, 2016, 74: 27-38.
Lan Y J, Wang H, Wu J S, et al. Cytokine storm-calming property of the isoquinoline alkaloids in Coptis chinensis Franch [J]. Front Pharmacol, 2022, 13: 973587.
Danielewski M, Zielińska S, Merwid-Ląd A, et al. Sanguinarine-chelerythrine from Coptis chinensis offers analgesic and anti-inflammatory effects without gastrotoxicity [J]. Pharmaceutics, 2025, 17(3): 323.
Chen Y Y, Cui W W, Li X, et al. Interaction between commensal bacteria, immune response and the intestinal barrier in inflammatory bowel disease [J]. Front Immunol, 2021, 12: 761981.
Zhou R, Huang Y Y, Tian C J, et al. Coptis chinensis and berberine ameliorate chronic ulcerative colitis: An integrated microbiome-metabolomics study [J]. Am J Chin Med, 2023, 51(8): 2195-2220.
Hu Y J, Chen Z Z, Xu C C, et al. Disturbances of the gut microbiota and microbiota-derived metabolites in inflammatory bowel disease [J]. Nutrients, 2022, 14(23): 5140.
Wang Y X, Zhang J Y, Cao Y M, et al. Coptis chinensis-induced changes in metabolomics and gut microbiota in rats [J]. Am J Chin Med, 2023, 51(6): 1547-1576.
Cosín-Roger J. Inflammatory bowel disease: Immune function, tissue fibrosis and current therapies [J]. Int J Mol Sci, 2024, 25(12): 6416.
Ye Q J, Huang S W, Wang Y, et al. Wogonin improves colitis by activating the AhR pathway to regulate the plasticity of ILC3/ILC1[J]. Phytomedicine, 2024, 128: 155425.
樊王冬, 于文倩. 甘油三酯-葡萄糖指数对炎性肠病发病风险的影响[J]. 中国医学科学院学报, 2025, 47(2): 251-258.
Bregenzer N, Hartmann A, Strauch U, et al. Increased insulin resistance and beta cell activity in patients with Crohn’s disease [J]. Inflamm Bowel Dis, 2006, 12(1): 53-56.
Kislinger T, Fu C, Huber B, et al. N(Epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression [J]. J Biol Chem, 1999, 274(44): 31740-31749.
Vlassara H, Cai W J, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy [J]. Proc Natl Acad Sci USA, 2002, 99(24): 15596-15601.
Mark A B, Poulsen M W, Andersen S, et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women [J]. Diabetes Care, 2014, 37(1): 88-95.
余刚. 膳食晚期糖基化终末产物AGEs介导食物过敏原致敏的免疫调控机制研究[D]. 杭州: 浙江工商大学, 2024.
Yang Y, Li Y, Yin D K, et al. Coptis chinensis polysaccharides inhibit advanced glycation end product formation [J]. J Med Food, 2016, 19(6): 593-600.
李宗祥, 马秋萍. 运动诱导代谢物变化在调节骨骼肌胰岛素抵抗中的作用[J]. 体育科研, 2024, 45(6): 79-91.
陈莉萍, 张艳蕾, 马梦玲, 等. 红景天苷通过抑制TNF-α/NF-κB通路改善C2C12细胞萎缩的研究[J]. 中国中医基础医学杂志, 2023, 29(4): 572-576.
Doğan A N, Kahraman R, Akar T. Evaluation of insulin resistance and beta cell activity in patients with inflammatory bowel disease [J]. Eur Rev Med Pharmacol Sci, 2022, 26(11): 3989-3994.
Chouliaras G, Panayotou I, Margoni D, et al. Circulating leptin and adiponectin and their relation to glucose metabolism in children with Crohn’s disease and ulcerative colitis [J]. Pediatr Res, 2013, 74(4): 420-426.
Yang T C, Chao H F, Shi L S, et al. Alkaloids from Coptis chinensis root promote glucose uptake in C2C12 myotubes [J]. Fitoterapia, 2014, 93: 239-244.
Goverse G, Stakenborg M, Matteoli G. The intestinal cholinergic anti-inflammatory pathway [J]. J Physiol, 2016, 594(20): 5771-5780.
Zheng W W, Song H, Luo Z G, et al. Acetylcholine ameliorates colitis by promoting IL-10 secretion of monocytic myeloid-derived suppressor cells through the nAChR/ERK pathway [J]. Proc Natl Acad Sci USA, 2021, 118(11): e2017762118.
Mogilevski T, Burgell R, Aziz Q, et al. Review article: The role of the autonomic nervous system in the pathogenesis and therapy of IBD [J]. Aliment Pharmacol Ther, 2019, 50(7): 720-737.
Serafini M A, Paz A H, Nunes N S. Cholinergic immunomodulation in inflammatory bowel diseases [J]. Brain Behav Immun Health, 2022, 19: 100401.
Cao T Q, Ngo Q T, Seong S H, et al. Cholinesterase inhibitory alkaloids from the rhizomes of Coptis chinensis [J]. Bioorg Chem, 2018, 77: 625-632.
Lin Y, Guo H C, Kuang Y, et al. AChE inhibitory alkaloids from Coptis chinensis [J]. Fitoterapia, 2020, 141: 104464.
Kong X P, Liu E Y L, Chen Z C, et al. Synergistic inhibition of acetylcholinesterase by alkaloids derived from Stephaniae Tetrandrae Radix, Coptidis Rhizoma and Phellodendri Chinensis Cortex [J]. Molecules, 2019, 24(24): 4567.
侯敏艳, 何亚萍, 邬宇, 等. 仙鹤草-黄连药对抗炎症性肠病的作用及其机制研究[J]. 时珍国医国药, 2023, 34(11): 2641-2647.
李阳. “黄连-干姜”药对预防炎症性肠病及其相关结肠癌作用机制研究[D]. 广州: 广州中医药大学, 2017.
Lim S M, Choi H S, Kim D H. The mixture of Anemarrhena asphodeloides and Coptis chinensis attenuates high-fat diet-induced colitis in mice [J]. Am J Chin Med, 2017, 45(5): 1033-1046.
周文, 张哲言, 黄莉, 等. 萸连丸对葡聚糖硫酸钠诱导的溃疡性结肠炎小鼠记忆性滤泡辅助性T细胞的调节作用[J]. 中药新药与临床药理, 2024, 35(2): 183-190.
Park E K, Rhee H I, Jung H S, et al. Antiinflammatory effects of a combined herbal preparation (RAH13) of Phellodendron amurense and Coptis chinensis in animal models of inflammation [J]. Phytother Res, 2007, 21(8): 746-750.
吴宇杰, 王停, 朱佩轩, 等. 基于数据挖掘的名医名家治疗溃疡性结肠炎辨证治疗规律研究[J]. 中医杂志, 2023, 64(21): 2241-2247.
方俐晖, 张佳琪, 胡蓝烁, 等. 葛根芩连汤加味方对溃疡性结肠炎模型小鼠肠黏膜屏障及上皮间质转化的影响[J]. 中医杂志, 2024, 65(24): 2580-2588.
黄金科, 张佳琪, 王凤云, 等. 加味葛根芩连汤对溃疡性结肠炎模型小鼠肠黏液屏障和肠道干细胞增殖分化的影响[J]. 中医杂志, 2025, 66(9): 941-947.
王婕, 鲍炳州, 石健, 等. 白头翁汤对湿热证溃疡性结肠炎大鼠结肠组织中脑肠肽和炎症因子的影响[J]. 安徽中医药大学学报, 2025, 44(5): 78-83.
宋迎. 白头翁汤治疗溃疡性结肠炎的疗效观察及对肠黏膜屏障功能和Th17/Treg相关细胞因子的影响[D]. 合肥: 安徽中医药大学, 2025.
刘尧, 李小明, 张海宏, 等. 芍药汤加减联合布拉氏酵母菌散治疗溃疡性结肠炎患者的疗效及对肠道菌群、肠黏膜屏障功能的影响[J]. 中国中西医结合消化杂志, 2025, 33(8): 776-780.
徐荣, 吴双双, 黄艳红, 等. 乌梅丸对溃疡性结肠炎大鼠结肠Rho/ROCK信号蛋白表达的影响[J]. 世界临床药物, 2025, 46(8): 751-756.
杨雪, 储琳. 半夏泻心汤在溃疡性结肠炎治疗中的应用[J]. 世界复合医学, 2025, 11(4): 67-71.
刘蕾蕾, 王书君, 梁书志, 等. 基于肠道自噬探讨半夏泻心汤治疗溃疡性结肠炎作用机制[J]. 中医药信息, 2025, 42(1): 1-7.
周策, 熊彦姣, 曹吉勋, 等. 溃疡性结肠炎厥阴病辨证探讨与寒热并用法的精准化应用研究[J]. 中国肛肠病杂志, 2023, 43(5): 66-71.
Zhou C, Peng B, Zhang M X, et al. Ganjiang Huangqin Huanglian Renshen Decoction protects against ulcerative colitis by modulating inflammation, oxidative stress, and gut microbiota [J]. Phytomedicine, 2024, 135: 156172.
周策, 易泽林, 张明星, 等. 干姜黄芩黄连人参汤通过NLRP3/Caspase-1途径对溃疡性结肠炎小鼠结肠上皮细胞焦亡的影响[J]. 中成药, 2025, 47(6): 1817-1824.
周鑫, 徐玲玲. 香连化滞丸联合柳氮磺吡啶治疗溃疡性结肠炎的效果[J]. 中国药物经济学, 2025, 20(7): 89-93.
杨晓庆, 张俊, 黄振, 等. 香连化滞丸联合美沙拉嗪治疗溃疡性结肠炎的临床研究[J]. 现代药物与临床, 2022, 37(9): 2044-2048.
何红霞, 范恒, 杨佳. 香连丸对溃疡性结肠炎小鼠泛凋亡途径的影响[J]. 华中科技大学学报: 医学版, 2024, 53(6): 717-722.
杨乐, 徐梦婷, 蔡琳玲, 等. UHPLC-TOF-MS结合网络药理学与实验验证探讨香连丸治疗溃疡性结肠炎的作用机制[J]. 中国药学杂志, 2023, 58(12): 1084-1092.
甘金刚, 樊海南, 张志强. 盐酸小檗碱对溃疡性结肠炎患者肠道菌群及免疫状态的影响[J]. 中国中西医结合消化杂志, 2020, 28(12): 949-953.
范安琪, 侯宝龙, 朱洁, 等. 基于代谢组学研究中药固肠止泻丸治疗小鼠溃疡性结肠炎的机制[J]. 中国新药杂志, 2024, 33(11): 1144-1154.

2026年第57卷第4期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.04.030

接收时间：2025-11-21
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-11-21

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.04.030

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT